| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 90999 |
|
63,101 |
4,379 |
$6.61M |
| Q4081 |
Injection, epoetin alfa, 100 units (for esrd on dialysis) |
35,004 |
2,179 |
$539K |
| J1270 |
Injection, doxercalciferol, 1 mcg |
27,169 |
2,106 |
$421K |
| J1756 |
Injection, iron sucrose, 1 mg |
12,301 |
2,502 |
$112K |
| A4657 |
Syringe, with or without needle, each |
14,075 |
3,324 |
$74K |
| 83970 |
|
3,119 |
1,835 |
$51K |
| 83540 |
|
3,288 |
2,075 |
$47K |
| 83550 |
|
2,233 |
1,675 |
$47K |
| 85048 |
|
2,910 |
1,885 |
$44K |
| 85041 |
|
2,942 |
1,897 |
$44K |
| 82728 |
|
3,036 |
1,991 |
$42K |
| J0604 |
Cinacalcet, oral, 1 mg, (for esrd on dialysis) |
1,531 |
382 |
$16K |
| 82108 |
|
937 |
607 |
$15K |
| 90674 |
|
110 |
87 |
$2K |
| G0008 |
Administration of influenza virus vaccine |
260 |
195 |
$1K |
| 87340 |
|
13 |
13 |
$651.10 |
| 90662 |
|
50 |
50 |
$646.60 |
| J0887 |
Injection, epoetin beta, 1 microgram, (for esrd on dialysis) |
1,557 |
578 |
$231.23 |
| G0499 |
Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result |
769 |
461 |
$15.45 |
| OP250 |
|
9,566 |
368 |
$0.00 |
| 0002A |
|
13 |
12 |
$0.00 |
| 0124A |
|
30 |
14 |
$0.00 |